1
|
Ji W, Liu H, Pan K, Huang R, Xu C, Wei Z, Wang J. Knowledge mapping analysis of safety ergonomics: a bibliometric study. ERGONOMICS 2024; 67:398-421. [PMID: 37288996 DOI: 10.1080/00140139.2023.2223788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Accepted: 06/06/2023] [Indexed: 06/09/2023]
Abstract
Although a significant attention, the field of safety ergonomics has not yet been systematically profiled based on recent studies. To fully understand the current research status, basis, hotspots, and development trends in the field, 533 documents from the Web of Science core database were used for knowledge mapping analysis by the bibliometric method. The study found that the USA is the top country in publications, and Tehran University is the institution with the highest number of publications. Ergonomics and Applied Economics are the authoritative safety ergonomics journals. Through co-occurrence and co-citation analysis, current safety ergonomics research is focussed on healthcare, product design, and occupational health and safety. The keyword timeline view indicates that the main research paths are occupational health and safety, and patient safety research. The analysis of burst keywords shows that safety ergonomics research in management, model design, and system design areas are research frontiers in the field.Practitioner summary: This paper presents a knowledge mapping of safety ergonomics research through bibliometric analysis. The research results show the research status, research hotspots, and research frontiers in the field of safety ergonomics, which provides a direction for other scholars to quickly understand the development of this field.
Collapse
Affiliation(s)
- Wenjing Ji
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Hui Liu
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Kai Pan
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Rui Huang
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Chang Xu
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Ze Wei
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| | - Jianhai Wang
- College of Quality and Safety Engineering, China Jiliang University, Hangzhou, China
| |
Collapse
|
2
|
Fuzesi P, Broadfoot K, Lennon M, Jacob SA, Macaden L, Smith A, Welsh T, Watson MC. The Burden of Managing Medicines for Older People With Sensory Impairment: An Ethnographic-Informed Study. Gerontol Geriatr Med 2024; 10:23337214241253410. [PMID: 38765919 PMCID: PMC11100380 DOI: 10.1177/23337214241253410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 04/21/2024] [Accepted: 04/22/2024] [Indexed: 05/22/2024] Open
Abstract
Background: Older age is associated with increased prevalence of sensory impairment and use of medicines. Objectives: To explore the daily "medicine journey" of older people with sensory impairment. Methods: The study used ethnographic-informed methods (using audio-, photo- and video-recordings, diary notes and semi-structured interviews with researchers) and involved community-dwelling adults (aged > 65) in Scotland, with visual and/or hearing impairment and using >4 medicines. Data analysis used the constant comparative method. Results: Fourteen older people with sensory impairment participated and used a mean of 11.0 (SD 5.0) medicines (range 5-22). Participants reported difficulties with medicine ordering, obtaining, storage, administration and disposal. They used elaborate strategies to manage their medicines including bespoke storage systems, fixed routines, simple aids, communication, and assistive technologies. Conclusion: Older people with sensory impairment experience substantial burden, challenges and risk with medicines management. Tailored medicine regimens and assistive technologies could provide greater support to older people with sensory impairment.
Collapse
Affiliation(s)
- Peter Fuzesi
- University of Strathclyde, Glasgow, Scotland, UK
| | | | | | - Sabrina Anne Jacob
- Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, Scotland, UK
| | | | - Annetta Smith
- University of the Highlands and Islands, Inverness, Scotland, UK
| | - Tomas Welsh
- Research Institute for the Care of Older People, Bath, UK
- Royal United Hospitals Bath, UK
- University of Bristol, UK
| | | |
Collapse
|
3
|
Patel VD, Patel DB, Sturgis JC, Queensen K, Sedlock R, Haware RV. Assessing the Impact of Punch Geometries on Tablet Capping Using a Newly Proposed Capping Index. Pharm Res 2023; 40:2935-2945. [PMID: 37380906 DOI: 10.1007/s11095-023-03555-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 06/16/2023] [Indexed: 06/30/2023]
Abstract
PURPOSE Increased tablet anisotropy could lead to increased tablet capping propensity. Tooling design variables such as cup depth could serve as a key player for inducing tablet anisotropy. METHODS A new capping index (CI) consisting of the ratio of compact anisotropic index (CAI) and material anisotropic index (MAI) is proposed to evaluate tablet capping propensity as a function of punch cup depth. CAI is the ratio of axial to radial breaking force. MAI is the ratio of axial to radial Young's modulus. The impact of various punch cup depths [flat face, flat face beveled edge, flat face radius edge, standard concave, shallow concave, compound concave, deep concave, and extra deep concave] on the capping propensity of model acetaminophen tablets was studied. Tablets were manufactured at 50, 100, 200, 250, and 300 MPa compression pressure at 20 RPM on different cup depth tools using Natoli NP-RD30 tablet press. A partial least squares model (PLS) was computed to model the impact of the cup depth and compression parameters on the CI. RESULTS The PLS model exhibited a positive correlation of increased cup depth to the capping index. The finite elemental analysis confirmed that a high capping tendency with increased cup depth is a direct result of non-uniform stress distribution across powder bed. CONCLUSIONS Certainly, a proposed new capping index with multivariate statistical analysis gives guidance in selecting tool design and compression parameters for robust tablets.
Collapse
Affiliation(s)
- Vivek D Patel
- Natoli Scientific, A Division of Natoli Engineering Company, Inc., 100 Emlen Way, Suite # 104-108, Telford, PA-18969, USA
| | - Devang B Patel
- Natoli Scientific, A Division of Natoli Engineering Company, Inc., 100 Emlen Way, Suite # 104-108, Telford, PA-18969, USA
| | - John C Sturgis
- Natoli Scientific, A Division of Natoli Engineering Company, Inc., 100 Emlen Way, Suite # 104-108, Telford, PA-18969, USA
| | - Kevin Queensen
- Natoli Engineering Company, Inc., Saint Charles, MO, 63304, USA
| | - Robert Sedlock
- Natoli Scientific, A Division of Natoli Engineering Company, Inc., 100 Emlen Way, Suite # 104-108, Telford, PA-18969, USA
| | - Rahul V Haware
- Natoli Scientific, A Division of Natoli Engineering Company, Inc., 100 Emlen Way, Suite # 104-108, Telford, PA-18969, USA.
| |
Collapse
|
4
|
Stegemann S, Sheehan L, Rossi A, Barrett A, Paudel A, Crean A, Ruiz F, Bresciani M, Liu F, Shariff Z, Shine M, Schmelzer C, Pense-Lheritier AM. Rational and practical considerations to guide a Target Product Profile for patient-centric drug product development with measurable patient outcomes - A proposed roadmap. Eur J Pharm Biopharm 2022; 177:81-88. [PMID: 35718077 DOI: 10.1016/j.ejpb.2022.06.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 06/12/2022] [Accepted: 06/13/2022] [Indexed: 11/29/2022]
Abstract
The increasing awareness of acceptability and usability of pharmaceutical drug products by the patient as a key quality requirement continues to drive need for integrating patient centric drug product design into the pharmaceutical development process. The complex matrix of multiple drug product related decisions during the early drug development process often limits patient-centric drug product (PCDP) design options in the final commercial drug product development phase. To integrate the specific needs and perspectives of patients into drug development and product design process, a rational approach integrated into the complex development matrix is required from the start and weighs product development decision options accordingly. The aim of this work was to develop a roadmap for PCDP design in a multidisciplinary approach that leads to better usability, adherence and acceptance of the drug by patients via early integration into the development matrix. The proposed rational approach is based upon regulatory requirements and lessons learned from pediatric and geriatric drug development.
Collapse
Affiliation(s)
- Sven Stegemann
- Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, 8010 Graz, Austria.
| | - Liz Sheehan
- SRL, Office of Technology 2-44, Western Gateway Building, University College Cork, Ireland.
| | - Alessandra Rossi
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.
| | - Andrew Barrett
- Drug Product Design, Pharmaceutical Sciences, Pfizer, Discovery Park House, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.
| | - Amrit Paudel
- Institute for Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, 8010 Graz, Austria; Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria.
| | - Abina Crean
- SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, Cork, Ireland.
| | - Fabrice Ruiz
- ClinSearch, 110 Avenue, Pierre Brossolette, 92240 Malakoff, France.
| | - Massimo Bresciani
- CMAC Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow G1 1RD, UK.
| | - Fang Liu
- Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
| | - Zakia Shariff
- School of Pharmacy, Aston University, Birmingham, B4 7ET, UK.
| | - Margarete Shine
- SRL, Office of Technology 2-44, Western Gateway Building, University College Cork, Ireland.
| | | | | |
Collapse
|
5
|
van Riet-Nales DA, van den Bemt B, van Bodegom D, Cerreta F, Dooley B, Eggenschwyler D, Hirschlérova B, Jansen PAF, Karapinar-Çarkit F, Moran A, Span J, Stegemann S, Sundberg K. Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. Br J Clin Pharmacol 2022; 88:1500-1514. [PMID: 35141926 DOI: 10.1111/bcp.15207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 12/09/2021] [Indexed: 11/28/2022] Open
Abstract
Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections are also relevant to younger patients with similar disease-related needs and of value to other stakeholders parties, e.g., healthcare professionals, academics, patients and caregivers, as the paper makes clear what can be expected from industry and where collaborative work is needed. This commentary provides an overview of the different steps in the development of the reflection paper, discusses points considered most controversial and/or subject to (multidisciplinary) expert discussions and indicates their value for real world clinical practice.
Collapse
Affiliation(s)
- Diana A van Riet-Nales
- Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands
| | - Bart van den Bemt
- Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands.,Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands
| | - David van Bodegom
- Public Health and Primary Care, Leyden Academy on Vitality and Ageing, Leiden, Netherlands.,Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, Netherlands
| | - Francesca Cerreta
- Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency, Amsterdam, Netherlands
| | - Brian Dooley
- Quality and Safety of Medicines Department, Human Medicines Division, European Medicines Agency, Amsterdam, Netherlands
| | | | - Blanka Hirschlérova
- Department of Pharmaceutical Assessment of Chemical and Herbal Products, State Institute for Drug Control (SUKL), Prague, Czech Republic
| | - Paul A F Jansen
- Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands.,Geriatric Department, University Medical Center, Utrecht, Netherlands.,Expertise Centre Pharmacotherapy in Old Persons (EPHOR), Utrecht, Netherlands
| | | | - Abigail Moran
- Medicines and Healthcare Products Regulatory Agency, London, UK
| | - Jan Span
- Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands
| | - Sven Stegemann
- Institute of Process and Particle Engineering, Graz University of Technology, Graz, Austria
| | - Katarina Sundberg
- Department of Pharmaceutics and Biotechnology, Swedish Medical Products Agency (MPA), Uppsala, Sweden
| |
Collapse
|
6
|
Stegemann S, van Riet‐Nales D, de Boer A. Demographics in the 2020s-Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. Br J Clin Pharmacol 2020; 86:1899-1903. [PMID: 32939841 PMCID: PMC7495272 DOI: 10.1111/bcp.14511] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/03/2020] [Accepted: 08/05/2020] [Indexed: 12/28/2022] Open
Affiliation(s)
- Sven Stegemann
- Institute of Process and Particle EngineeringGraz University of TechnologyGrazAustria
| | | | | |
Collapse
|
7
|
van Riet-Nales DA, Sundberg K, de Boer A, Hirschlérova B. Developing patient-centric medicines for older people: Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population. Br J Clin Pharmacol 2020; 86:2008-2013. [PMID: 32830323 DOI: 10.1111/bcp.14530] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Revised: 06/03/2020] [Accepted: 08/04/2020] [Indexed: 12/23/2022] Open
Abstract
Increased global longevity requires a re-evaluation of current structures in society to adapt to the consequential demographic shift. As (very) old people are prone to impaired human organ and body functions resulting in, for example, multimorbidity, polypharmacy, hospitalisation and problems in medication management, it is increasingly acknowledged that re-evaluations should include the suitability of pharmaceutical patient care as one of the cornerstones of public health. Following the 2011 European Medicines Agency (EMA) Geriatric Strategy, in 2017 the EMA published the draft "Reflection paper on the pharmaceutical development of medicines for use in the older population". The draft paper was opened for public consultation and specific attention and feedback (either supportive or with a proposal for revision) was asked on three design aspects: tablet breaking, drug administration through enteral feeding tubes and medication management. Following publication, the draft paper was presented at two public conferences attended by participants from different disciplines. This manuscript is intended to draw the attention of different stakeholder parties to the urgent need to collaborate on the emerging issues arising from increasing longevity and multimorbidity, and especially those associated with pharmaceutical patient care and drug product design, including the need for collaborative research into existing or emerging knowledge gaps. The manuscript focuses on the three aforementioned aspects of pharmaceutical development (tablet breaking, drug administration through enteral feeding tubes and medication management) as these highly relate to medication safety and efficacy and constitute persistent and typical challenges for older people, caregivers and healthcare professionals in daily clinical practice.
Collapse
Affiliation(s)
- Diana A van Riet-Nales
- Medicines Evaluation Board, DVRN: International Collaboration Center, ADB: Chair of MEB, Utrecht, the Netherlands
| | - Katarina Sundberg
- Department of Pharmaceutics and Biotechnology, Swedish Medical Products Agency, Uppsala, Sweden
| | - Anthonius de Boer
- Medicines Evaluation Board, DVRN: International Collaboration Center, ADB: Chair of MEB, Utrecht, the Netherlands
| | - Blanka Hirschlérova
- Department of Pharmaceutical Assessment of Chemical and Herbal Products, State Institute for Drug Control, Prague, Czech Republic
| |
Collapse
|
8
|
Feufel MA, Rauwolf G, Meier FC, Karapinar-Çarkit F, Heibges M. Heuristics for designing user-centric drug products: Lessons learned from Human Factors and Ergonomics. Br J Clin Pharmacol 2019; 86:1989-1999. [PMID: 31663157 PMCID: PMC7495287 DOI: 10.1111/bcp.14134] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 07/19/2019] [Accepted: 09/02/2019] [Indexed: 11/27/2022] Open
Abstract
Even the most effective drug product may be used improperly and thus ultimately prove ineffective if it does not meet the perceptual, motor and cognitive capacities of its target users. Currently, no comprehensive guideline for systematically designing user‐centric drug products that would help prevent such limitations exists. We have compiled a list of approximate but nonetheless useful strategies—heuristics—for implementing a user‐centric design of drug products and drug product portfolios. First, we present a general heuristic for user‐centric design based on the framework of Human Factors and Ergonomics (HF/E). Then we demonstrate how to implement this general heuristic for older drug users (i.e., patients and caregivers aged 65 years and older) and with respect to three specific challenges (use‐cases) of medication management: (A) knowing what drug product to take/administer, (B) knowing how and when to take/administer it, and (C) actually taking/administering it. The presented heuristics can be applied prospectively to include existing knowledge about user‐centric design at every step during drug discovery, pharmaceutical drug development, and pre‐clinical and clinical trials. After a product has been released to the market, the heuristics may guide a retrospective analysis of medication errors and barriers to product usage as a basis for iteratively optimizing both the drug product and its portfolio over their life cycle.
Collapse
Affiliation(s)
- Markus A Feufel
- Department of Psychology and Ergonomics, Division of Ergonomics, Technische Universität Berlin, Berlin, Germany
| | - Gudrun Rauwolf
- Department of Psychology and Ergonomics, Division of Ergonomics, Technische Universität Berlin, Berlin, Germany
| | - Felix C Meier
- Department of Psychology and Ergonomics, Division of Ergonomics, Technische Universität Berlin, Berlin, Germany
| | | | - Maren Heibges
- Department of Psychology and Ergonomics, Division of Ergonomics, Technische Universität Berlin, Berlin, Germany
| |
Collapse
|